Leslie E. Oldfield

Leslie E. Oldfield

Auto-generated profile, based on publicly available information

Leslie E. Oldfield

School of Pharmacy, The University of Queensland, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DWDerek Wong
Derek Wong
PLPing Luo
Ping Luo
LOLeslie E. Oldfield
Leslie E. Oldfield
HGHaifan Gong
Haifan Gong
LBLedia Brunga
Ledia Brunga
TPTrevor J Pugh
Trevor J Pugh
People with Li–Fraumeni syndrome (LFS) harbor a germline pathogenic variant in the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely undergo intensive surveillance protocols. Liquid biopsy has become an attractive tool for a range of clinical applications, including early cancer detection. Here, we provide a proof-of-principle for a multimodal liquid biopsy assay that integrates a targeted gene panel, shallow whole-genome, and cell-free methylated DNA immunoprecipitation sequencing for the early detection of cancer in a longitudinal cohort of 89 LFS patients. Multimodal analysis increased our detection rate in patients with an active cancer diagnosis over uni-modal analysis and was able to detect cancer-associated signal(s) in carriers prior to diagnosis with conventional screening (positive predictive value = 67.6%, negative predictive value = 96.5%). Although adoption of liquid biopsy into current surveillance will require further clinical validation, this study provides a framework for individuals with LFS. Significance: By utilizing an integrated cell-free DNA approach, liquid biopsy shows earlier detection of cancer in patients with LFS compared with current clinical surveillance methods such as imaging. Liquid biopsy provides improved accessibility and sensitivity, complementing current clinical surveillance methods to provide better care for these patients. See related commentary by Latham et al., p. 23. This article is featured in Selected Articles from This Issue, p. 5

16 June 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SLStephanie Lheureux
Stephanie Lheureux
SPStephenie Prokopec
Stephenie Prokopec
LOLeslie E. Oldfield
Leslie E. Oldfield
EGEduardo Gonzalez-Ochoa
Eduardo Gonzalez-Ochoa
JBJeff Bruce
Jeff Bruce
TPTrevor J Pugh
Trevor J Pugh
Purpose: To evaluate the use of blood cell–free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high-grade serous ovarian cancer (HGSOC). Experimental Design: We used targeted sequencing (TS) to analyze 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2, and at end of treatment. These were compared with whole-exome sequencing (WES) of baseline tumor tissues. Results: At baseline (time of initial PARPi progression), cfDNA tumor fractions were 0.2% to 67% (median, 3.25%), and patients with high ctDNA levels (>15%) had a higher tumor burden (sum of target lesions; P = 0.043). Across all timepoints, cfDNA detected 74.4% of mutations known from prior tumor WES, including three of five expected BRCA1/2 reversion mutations. In addition, cfDNA identified 10 novel mutations not detected by WES, including seven TP53 mutations annotated as pathogenic by ClinVar. cfDNA fragmentation analysis attributed five of these novel TP53 mutations to clonal hematopoiesis of indeterminate potential (CHIP). At baseline, samples with significant differences in mutant fragment size distribution had shorter time to progression (P = 0.001). Conclusions: Longitudinal testing of cfDNA by TS provides a noninvasive tool for detection of tumor-derived mutations and mechanisms of PARPi resistance that may aid in directing patients to appropriate therapeutic strategies. With cfDNA fragmentation analyses, CHIP was identified in several patients and warrants further investigation.

1 April 2022 in Journal of Pain and Symptom Management
Verified
Journal Article
Open access
ABAfsan Bhadelia
Afsan Bhadelia
LOLeslie E. Oldfield
Leslie E. Oldfield
JCJennifer L. Cruz
Jennifer L. Cruz
RSRatna Singh
Ratna Singh
EFEric A. Finkelstein
Eric A. Finkelstein
There is growing recognition of the value to patients, families, society, and health systems in providing healthcare, including end-of-life care, that is consistent with both patient preferences and clinical guidelines. Identify the core domains and subdomains that can be used to evaluate the performance of end-of-life care within and across health systems. PubMed/MEDLINE (NCBI), PsycINFO (ProQuest), and CINAHL (EBSCO) databases were searched for peer-reviewed journal articles published prior to February 22, 2020. The SPIDER tool was used to determine search terms. A priori criteria were followed with independent review to identify relevant articles. A total of 309 eligible articles were identified out of 2728 discrete results. The articles represent perspectives from the broader health system (11), patients (70), family and informal caregivers (65), healthcare professionals (43), multiple viewpoints (110), and others (10). The most common condition of focus was cancer (103) and the majority (245) of the studies concentrated on high-income country contexts. The review identified five domains and 11 subdomains focused on structural factors relevant to end-of-life care at the broader health system level, and two domains and 22 subdomains focused on experiential aspects of end-of-life care from the patient and family perspectives. The structural health system domains were: 1) stewardship and governance, 2) resource generation, 3) financing and financial protection, 4) service provision, and 5) access to care. The experiential domains were: 1) quality of care, and 2) quality of communication. The review affirms the need for a people-centered approach to managing the delicate process and period of accepting and preparing for the end of life. The identified structural and experiential factors pertinent to the "quality of death" will prove invaluable for future efforts aimed to quantify health system performance in the end-of-life period.

1 February 2021 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
LOLeslie E. Oldfield
Leslie E. Oldfield
TLTiantian Li
Tiantian Li
ATAlicia Tone
Alicia Tone
MAMelyssa Aronson
Melyssa Aronson
MEMelissa Edwards
Melissa Edwards
TPTrevor J Pugh
Trevor J Pugh
Clinical testing for mismatch repair (MMR) deficiency often entails serial testing of tumour and constitutional DNA using multiple assays. To minimize cost and specimen requirements of MMR testing, we developed an integrated targeted sequencing protocol (termed MultiMMR) that tests for promoter methylation, mutations, copy number alterations, copy neutral loss-of-heterozygosity, and microsatellite instability from a single aliquot of DNA. We performed hybrid capture of DNA sequencing libraries constructed with methylated adapters on 142 samples (60 tumours and 82 constitutional samples) from 82 patients with MMR-associated colorectal, endometrial, and brain cancers as well as a synthetic DNA mix with 11 known mutations. We then split the captured material to enable parallel bisulfite and conventional sequence analysis. The panel targeted microsatellite regions and 13 genes associated with MMR, hypermutation, and hereditary colorectal cancer. MultiMMR recapitulated clinical testing results in 23/24 cases, was able to explain MMR loss in an additional 29/48 patients with incomplete/inconclusive testing, and identified all 11 MMR variants within the synthetic DNA mix. Promoter methylation and microsatellite instability analysis showed 95% and 97% concordance with clinical testing, respectively. We demonstrated feasibility for amalgamation of the current stepwise and complex clinical testing workflow into an integrated test for both hereditary and somatic causes of MMR deficiency.

27 September 2024 in Trials
Verified
Journal Article
Open access
PDF file
Hendrika Laetitia HattinghHendrika Laetitia Hattingh
Hendrika Laetitia Hattingh
MBMelissa T. Baysari
Melissa T. Baysari
HFHolly Foot
Holly Foot
TSTin Fei Sim
Tin Fei Sim
GKGerben Keijzers
Gerben Keijzers
EMElizabeth Manias
Elizabeth Manias
Background: General practitioners (GP) and community pharmacists need information about hospital discharge patients’ medicines to continue their management in the community. This necessitates effective communication, collaboration, and reliable information-sharing. However, such handover is inconsistent, and whilst digital systems are in place to transfer information at transitions of care, these systems are passive and clinicians are not prompted about patients’ transitions. There are also gaps in communication between community pharmacists and GPs. These issues impact patient safety, leading to hospital readmissions and increased healthcare costs. Methods: A three-phased, multi-method study design is planned to trial a multifaceted intervention to reduce 30-day hospital readmissions. Phase 1 is the co-design of the intervention with stakeholders and end-users; phase 2 is the development of the intervention; phase 3 is a stepped wedge cluster randomised controlled trial with 20 clusters (community pharmacies). Expected intervention components will be a hospital pharmacist navigator, primary care medication management review services, and a digital solution for information sharing. Phase 3 will recruit 10 patients per pharmacy cluster/month to achieve a sample size of 2200 patients powered to detect a 5% absolute reduction in unplanned readmissions from 10% in the control group to 5% in the intervention at 30 days. The randomisation and intervention will occur at the level of the patient’s nominated community pharmacy. Primary analysis will be a comparison of 30-day medication-related hospital readmissions between intervention and control clusters using a mixed effects Poisson regression model with a random effect for cluster (pharmacy) and a fixed effect for each step to account for secular trends. Trial registration: This trial is registered with the Australian New Zealand Clinical Trials Registry: ACTRN12624000480583p, registered 19 April 2024.

12 January 2024
Verified
Other
Open access
DWDerek Wong
Derek Wong
PLPing Luo
Ping Luo
LOLeslie E. Oldfield
Leslie E. Oldfield
HGHaifan Gong
Haifan Gong
LBLedia Brunga
Ledia Brunga
TPTrevor J Pugh
Trevor J Pugh
Supplemental Table 1 – Sample Descriptions